These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10098769)

  • 1. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas.
    Mann B; Gratchev A; Böhm C; Hanski ML; Foss HD; Demel G; Trojanek B; Schmidt-Wolf I; Stein H; Riecken EO; Buhr HJ; Hanski C
    Br J Cancer; 1999 Mar; 79(7-8):1262-9. PubMed ID: 10098769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
    J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
    J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
    Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
    Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence.
    Belluco C; Esposito G; Bertorelle R; Alaggio R; Giacomelli L; Bianchi LC; Nitti D; Lise M
    Eur J Surg Oncol; 2002 Mar; 28(2):120-5. PubMed ID: 11884046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
    Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells.
    Schneider-Stock R; Kuester D; Ullrich O; Mittag F; Habold C; Boltze C; Peters B; Krueger S; Hintze C; Meyer F; Hartig R; Roessner A
    J Pathol; 2006 May; 209(1):95-105. PubMed ID: 16575786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma.
    Li SY; Yu B; An P; Wei JC; Zuo FY; Cai HY
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):226-9. PubMed ID: 15138115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of metallothionein and FasL in colorectal cancer and its clinical significance].
    Li SY; Yu B; An P; Zuo FY; Cai HY
    Zhonghua Wai Ke Za Zhi; 2005 Sep; 43(17):1118-20. PubMed ID: 16194308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of FasL gene expression upon hepatic metastasis of colorectal carcinoma].
    Li SY; Yu B; An P; Wei JC; Zhang YN; Cai HY
    Zhonghua Wai Ke Za Zhi; 2003 Sep; 41(9):646-468. PubMed ID: 14680559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
    Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
    Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
    O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
    J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human lung carcinomas express Fas ligand.
    Niehans GA; Brunner T; Frizelle SP; Liston JC; Salerno CT; Knapp DJ; Green DR; Kratzke RA
    Cancer Res; 1997 Mar; 57(6):1007-12. PubMed ID: 9067260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human colon cancer cells express the functional Fas ligand.
    Ding EX; Hizuta A; Morimoto Y; Tanida T; Hongo T; Ishii T; Yamano T; Fujiwara T; Iwagaki H; Tanaka N
    Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):13-24. PubMed ID: 9755840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
    Kato H; Semba S; Miskad UA; Seo Y; Kasuga M; Yokozaki H
    Clin Cancer Res; 2004 Nov; 10(21):7318-28. PubMed ID: 15534108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
    Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.